glp 1 coverage

GLP-1 Coverage Trends Heading Into 2027

November 9, 2026

Key Takeaways

Audit your formulary, utilization, spending, and approval delays before changing GLP-1 benefits.
Balance access and cost.
Communicate copays, deductibles, denials, and appeal steps clearly.
Pair GLP-1 coverage with coaching and nutrition support to improve persistence.
Track changing employer, Medicare, Medicaid, and direct-to-consumer pricing options.

A females hand holding a glp1 medication injection pen for treatment

The Inside Rx Blog

Get the Inside Scoop on tips & tricks that may help your family save on prescriptions!

Subscribe to stay up to date with the latest news and tips

Employer support for GLP-1 medications has dropped from 72% in 2025 to 60% in 2026, with 14% of employers planning to eliminate these drugs from their plans entirely by 2027. Healthcare costs are projected to climb 9.2% without benefit design changes, putting additional pressure on benefits teams to reassess pharmacy strategy.

The public sector is moving differently. Medicare's GLP-1 Bridge Program gives eligible beneficiaries access at $50 per month through 2027, a figure that stands in sharp contrast to what employees on employer-sponsored plans are facing. These two tracks, public and private GLP-1 insurance coverage, are diverging on cost, access, and design in ways that have direct implications for benefits planning.

This article covers four areas: auditing your current GLP-1 benefits, evaluating cost management approaches, equipping employees with accurate cost information, and tracking the policy and market shifts expected through 2027.

Start With a Review of Your Current GLP-1 Benefits

A benefits audit is the starting point. Without a clear account of what your plan currently covers, cost and access decisions become reactive rather than deliberate.

Check which drugs and prescribed uses your plan covers

Pull your formulary and list every GLP-1 medication included, along with the specific indications that qualify. The distinctions matter: Wegovy and Zepbound hold FDA approval for weight loss and related conditions, cardiovascular risk reduction and moderate to severe obstructive sleep apnea among them, while Ozempic and Mounjaro are approved only for type 2 diabetes, though both are frequently prescribed off-label for weight loss. Plans often cover one indication and exclude the other, so confirm whether your formulary separates diabetes indications from weight-management ones. Currently, 55% of employers cover GLP-1s for diabetes, while 36% extend coverage to both diabetes and weight loss. Scale plays a role here: 43% of firms with 5,000 or more workers cover GLP-1s for weight loss, compared with roughly one in five companies with 200 or more employees.

Review employee use and total pharmacy spending

GLP-1 prescriptions for weight loss accounted for 10.5% of total pharmacy claims in 2025, up from 6.9% in 2023, a shift that moves these drugs from a secondary budget concern to a primary one. For 27% of employers, GLP-1 costs now make up more than 15% of annual claims. Pharmacy spending overall sits at 25% of employer healthcare budgets and is projected to rise 12% in 2027. Two-thirds of employers reported increased utilization, and 66% of the largest employers said weight-loss GLP-1 coverage had a significant impact on prescription drug spending.

Identify approval delays and treatment gaps

What a plan covers and what employees can actually access are two different things. Prior authorization creates measurable friction: only 11% of initially rejected prescriptions are resolved the same day, 44% take a median of six days to clear review, and 45% are denied outright. Approval rates differ by drug, tirzepatide sits at 49%, the lowest among major GLP-1 medications. Each day a prescription sits in review is a day without treatment, a gap that compounds the "GLP-1 desert" problem affecting areas with already limited access.

Compare current benefits with proposed 2027 changes

With utilization data and access gaps documented, the next step is measuring your plan against what's changing nationally. Starbucks announced it will drop GLP-1 coverage for weight loss for benefits-eligible employees starting in October, one of the more visible examples of how cost pressure is forcing employer decisions. On the public side, the Medicaid portion of the BALANCE Model opened for state participation between May 2026 and January 2027, while the Medicare GLP-1 Bridge Program, launched in July 2026, was extended through the end of 2027. These shifts in GLP-1 insurance coverage affect employee out-of-pocket costs directly, which makes early communication, including information about options like Inside Rx, worth building into your planning timeline before employees encounter changes on their own.

Compare Ways to Manage GLP-1 Coverage Costs

Identifying coverage gaps is only part of the work. The harder question is how to control costs without eliminating access entirely. Employers are currently working through several approaches, and each one carries tradeoffs between budget relief and benefit breadth.

Keeping coverage versus narrowing or ending it

Cost pressure has pushed employers in different directions. Currently, 54% of companies offering GLP-1s for weight loss restrict access to a subset of eligible employees rather than extending it to all who qualify. Others have shifted to diabetes-only coverage, keeping GLP-1 insurance coverage in place for medically necessary cases while removing the weight-loss indication that tends to drive the highest volume of claims.

Using clinical criteria to guide access

For employers unwilling to cut coverage outright, clinical criteria provide a way to manage which employees qualify. Prior authorization is the most widely used tool, applied by 80% of employers, followed by criteria that exceed FDA labeling at 54%, restrictions to specific GLP-1 drugs at 43%, and step therapy at 13%. One complication worth noting: PBMs may pull manufacturer rebates when employers tighten BMI thresholds or restrict access to non-network prescribers, since those rebate agreements are frequently tied to broader formulary participation.

Pairing medication benefits with lifestyle support

Persistence is a known problem with GLP-1 therapy. Only about 14% of patients remain on GLP-1 therapy after three years, and most who discontinue regain a substantial portion of lost weight. Behavioral support, coaching, nutrition guidance, structured follow-up, improves those numbers, yet just 14% of companies currently offer a third-party wraparound program. The gap between demand and supply is notable: 70% of employees say they would value such a program, while only 20% currently have access to one.

Reviewing pharmacy contracts and funding options

Plan design decisions interact directly with how pharmacy contracts are structured. PBMs pass roughly 91% of manufacturer rebates to insurers on average, though the method of calculation is rarely transparent to employers. About 32% of employers expect to move to a transparent or next-generation PBM model by 2027, with another 47% weighing the same shift in 2028 or 2029. Some employers are also testing direct-to-consumer reimbursement arrangements or HRAs outside standard PBM contracts, steering employees toward savings tools such as Inside Rx to manage out-of-pocket costs without absorbing the full expense of broad glp-1 coverage.

Help Employees Understand Their Costs and Options

Knowing your cost strategy internally is one part of the equation. Employees also need clear, accurate information about what they will actually pay, before they encounter a denial or an unexpected bill.

Explain copays, deductibles, and costs without coverage

Without coverage, GLP-1 medications can run over $1,000 a month, a figure most employees have no reference point for. Walk through what their copay covers, how the deductible applies, and what the plan excludes for a specific drug or clinical indication. Coverage rules differ by plan type and clinical criteria, so a single generic explanation will not hold up across your employee population.

Provide clear steps for coverage questions and appeals

Point employees to their Summary of Benefits and Coverage document, which every plan is required to provide. A direct contact for prior authorization denials and a defined appeals path are equally important, incomplete paperwork is among the most common reasons requests stall rather than move forward.

Present Inside Rx as a potential savings option for eligible prescriptions at participating pharmacies

Inside Rx is accepted at 60,000 pharmacies nationwide, with average savings of 78% on generics and 37% on select brand medications. For employees facing a coverage gap on a GLP-1 prescription, this reduces out-of-pocket cost at participating locations.

Explain that prescription discounts are not insurance and savings vary

Inside Rx is not insurance and cannot be used alongside insurance benefits or copay assistance programs. Employees enrolled in Medicare, Medicaid, or Tricare face restrictions on certain featured brand medications, and actual savings differ by pharmacy and prescription.

Encourage employees to discuss treatment changes with their prescriber

A clinician is the appropriate starting point for confirming clinical eligibility, submitting prior authorization, and identifying alternatives when an insurer denies a request.

Track Policy and Market Changes Through 2027

The gap between public and private GLP-1 coverage programs is measurable now and will grow wider through 2027. Benefits teams that treat these two tracks as equivalent will find themselves caught off guard when employees' situations don't match the plan they designed.

How the GLP-1 Bridge Program differs from employer coverage

Federal costs for Bridge Program enrollees remain fixed, while employer-sponsored GLP-1 insurance coverage continues to contract. A WTW survey found that 53% of employers with more than 100 workers cover GLP-1s for weight loss, down from 57% in 2025, the first decline recorded in three years. 16% are now considering removing coverage entirely, up from 9% a year earlier. These two programs serve different populations under different financial rules, so knowing which pool each employee falls into is a necessary part of benefits administration, not an optional one.

What the Medicare BALANCE delay and Medicaid state choices leave uncertain

Marsh projects an 8.2% rise in per-employee health costs for 2027, the sharpest increase since 2003, with GLP-1 utilization alone responsible for a full percentage point of that figure. Ellen Kelsay of Business Group on Health described this as "an unfortunate new reality" for budgeting and forecasting. Medicaid's BALANCE Model introduced additional variables, as state participation decisions between May 2026 and January 2027 created uneven coverage landscapes that affect employees in different regions differently.

How new drugs and pricing changes could shape future benefits

Direct-to-consumer pricing is introducing a parallel channel that some employers are factoring directly into plan design. Wegovy is priced at $149 per month for pills and $199 for injections; Zepbound starts at $299. Rather than routing these costs through a PBM, some employers now reimburse a portion of the direct-to-consumer price, while others redirect employees toward biosimilars or vendor-managed weight programs priced between $65 and $100 monthly. Both approaches represent a structural departure from traditional pharmacy benefit design and warrant close review as pricing on newer agents continues to shift.

The Inside Rx prescription discount card works like a coupon to save on the cost of prescription medication at your local pharmacy.

Wegovy

^$ 149.00

Tablet, 1.5 Mg

30 Tablets

Mounjaro

^$ 227.96

Pen Injector (0.5ml Syringe), 15mg/0.5ml

1 Package

Conclusion

The direction of GLP-1 coverage through 2027 is clear: employer support is contracting, public programs are expanding on separate terms, and pharmacy costs continue to rise faster than most benefit budgets anticipated. Benefits teams that audit their current formularies, apply cost-control strategies with defined clinical criteria, and communicate accurate cost information to employees will be better positioned to manage those pressures without leaving employees without options.

Inside Rx offers one practical tool for employees who face coverage gaps, with access across 60,000 participating pharmacies and documented savings on both generics and select brand medications. It is not insurance and cannot replace coverage, but for eligible employees dealing with out-of-pocket costs on GLP-1 prescriptions, it provides a concrete alternative worth including in any benefits communication plan.

References

Topics:

Business & Employers Weight Loss